AU2001253140A1 - Tumor markers in ovarian cancer - Google Patents

Tumor markers in ovarian cancer

Info

Publication number
AU2001253140A1
AU2001253140A1 AU2001253140A AU5314001A AU2001253140A1 AU 2001253140 A1 AU2001253140 A1 AU 2001253140A1 AU 2001253140 A AU2001253140 A AU 2001253140A AU 5314001 A AU5314001 A AU 5314001A AU 2001253140 A1 AU2001253140 A1 AU 2001253140A1
Authority
AU
Australia
Prior art keywords
ovarian cancer
tumor markers
markers
tumor
ovarian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253140A
Inventor
Colleen D. Hough
Patrice J. Morin
Ellen S. Pizer
Cheryl A. Sherman-Baust
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2001253140A1 publication Critical patent/AU2001253140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
AU2001253140A 2000-04-03 2001-04-03 Tumor markers in ovarian cancer Abandoned AU2001253140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19433600P 2000-04-03 2000-04-03
US60/194,336 2000-04-03
PCT/US2001/010947 WO2001075177A2 (en) 2000-04-03 2001-04-03 Tumor markers in ovarian cancer

Publications (1)

Publication Number Publication Date
AU2001253140A1 true AU2001253140A1 (en) 2001-10-15

Family

ID=22717190

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253140A Abandoned AU2001253140A1 (en) 2000-04-03 2001-04-03 Tumor markers in ovarian cancer

Country Status (3)

Country Link
US (3) US7279294B2 (en)
AU (1) AU2001253140A1 (en)
WO (1) WO2001075177A2 (en)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
WO2001075177A2 (en) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
US20020115626A1 (en) * 2000-05-25 2002-08-22 Luca Rastelli Method of detecting inflammatory lung disorders
AU2002223568A1 (en) * 2000-09-27 2002-04-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Identification of neuroblastoma tumor suppressor genes
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) * 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20060210474A1 (en) * 2000-11-29 2006-09-21 Young David S Cytotoxicity mediation of cells evidencing surface expression of CD63
WO2003000113A2 (en) * 2001-06-20 2003-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP1435389A4 (en) * 2001-09-04 2006-02-22 Nippon Shinyaku Co Ltd Method of evaluating efficacy of nucleic acid therapy
US7074576B2 (en) * 2001-11-23 2006-07-11 Syn X Pharma, Inc. Protein biopolymer markers indicative of alzheimer's disease
AU2002335967A1 (en) * 2001-11-23 2003-06-10 Syn. X Pharma, Inc. Protein biopolymer markers predictive of alzheimers disease
US20030113808A1 (en) * 2001-12-13 2003-06-19 George Jackowski Apolipoprotein biopolymer markers predictive of alzheimers disease
AU2003216288B2 (en) * 2002-02-13 2009-09-24 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
WO2003075854A2 (en) * 2002-03-07 2003-09-18 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
EP1354963A1 (en) * 2002-04-15 2003-10-22 Health Research, Inc. Method for determining the prognosis of ovarian cancer
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
CA2492160A1 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) * 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
GB0216727D0 (en) 2002-07-17 2002-08-28 Univ Cambridge Tech Genes
NZ563328A (en) 2002-10-16 2009-08-28 Euro Celtique Sa Antibodies that bind cell-associated CA 125/0772P and methods of use thereof
US7700307B2 (en) * 2003-03-08 2010-04-20 Auvation Limited Mitochondrial stress-70 protein markers for colorectal cancer
JP2007534611A (en) * 2003-04-08 2007-11-29 ジェノバ・リミテッド Secreted polypeptide species associated with cardiovascular disorders
CA2523870A1 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
CA2532035A1 (en) * 2003-07-07 2005-02-03 The General Hospital Corporation Fugetactic proteins, compositions and methods of use
ATE528397T1 (en) 2003-08-08 2011-10-15 Perseus Proteomics Inc GENE OVEREXPRESSED IN CANCER
US8603481B2 (en) * 2003-10-10 2013-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for solid tumors
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
WO2005066371A2 (en) * 2003-12-31 2005-07-21 The Penn State Research Foundation Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
AU2005265309A1 (en) * 2004-07-09 2006-01-26 Tripath Imaging, Inc. Methods and compositions for the detection of ovarian cancer
WO2006010498A2 (en) * 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
AT501014A1 (en) * 2004-08-19 2006-05-15 Kury & Zeillinger Oeg METHOD AND KIT FOR THE DIAGNOSIS OF A CANCER DISEASE, METHOD FOR DETERMINING THE APPEAL OF A PATIENT FOR THE TREATMENT OF CANCER DISEASE, THERAPEUTIC AGAINST THE PROPHYLAXIS OR THE TREATMENT OF A CANCER DISEASE
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
DK3332808T3 (en) * 2005-03-03 2020-12-14 Immunomedics Inc Humanized L243 antibodies
EP1748080A3 (en) * 2005-03-11 2007-04-11 Epiontis GmbH Specific DNAs for epigenetic characterisation of cells and tissues
US8298762B2 (en) 2005-03-11 2012-10-30 Epiontis Gmbh Specific DNAS for Epigenetic Characterisation of cells and tissues
WO2006119155A2 (en) * 2005-05-02 2006-11-09 The Brigham And Women's Hospital, Inc. Diagnostic serum antibody profiling
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
WO2007060747A1 (en) * 2005-11-22 2007-05-31 Galpharma Co., Ltd. Galectin-9 induction factor
AU2006350220A1 (en) * 2005-12-23 2008-05-08 Board Of Regents Of The University Of Texas System Anti-hyperproliferative therapies targeting HDGF
KR20080114689A (en) 2006-02-09 2008-12-31 유니버시티 오브 사우스 플로리다 Detection of cancer by elevated levels of bcl-2
NZ545243A (en) * 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
EP2028492A4 (en) * 2006-06-05 2009-06-10 Shimadzu Corp Tumor marker and method for determination of the occurrence of cancerous disease
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
US8076061B2 (en) * 2007-09-07 2011-12-13 Ascentgene, Inc. Method and composition for cancer diagnosis and treatment
WO2009099561A2 (en) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Urinary ca125 peptides as biomarkers of ovarian cancer
US8476026B2 (en) * 2008-04-01 2013-07-02 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
CN102274501A (en) * 2008-09-07 2011-12-14 苏州爱生基因有限公司 Medicine for treating and preventing cancers
CN102274509A (en) * 2008-09-07 2011-12-14 苏州爱生基因有限公司 Medicament for treating or preventing cancer
CN101664550A (en) * 2008-09-07 2010-03-10 苏州爱生基因有限公司 Method and medicament for treating or preventing cancers
CN102274507A (en) * 2008-09-07 2011-12-14 苏州爱生基因有限公司 Medicament for treating or preventing cancer
CN102274503A (en) * 2008-09-07 2011-12-14 苏州爱生基因有限公司 Medicament for treating or preventing cancers
CN102274499A (en) * 2008-09-07 2011-12-14 苏州爱生基因有限公司 Medicine for treating and preventing cancers
CN102274506A (en) * 2008-09-07 2011-12-14 苏州爱生基因有限公司 Medicine for treating and preventing cancer
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
IT1392551B1 (en) * 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A BIOMARCERS FOR DIAGNOSIS AND TO DETECT THE PROGRESSION OF NEURODEGENERATIVE DISEASES, IN PARTICULAR OF AMIOTROPHIC LATERAL SCLEROSIS
FI20090161A0 (en) 2009-04-22 2009-04-22 Faron Pharmaceuticals Oy New cell and therapeutical and diagnostic methods based on it
AU2014203702B2 (en) * 2009-07-07 2016-04-21 Protgen Ltd. New tumor marker
CN101942017B (en) * 2009-07-07 2013-08-14 清华大学 Tumor marker
JP2013504585A (en) 2009-09-09 2013-02-07 セントローズ， エルエルシー Extracellular targeted drug complex
EP2504363B1 (en) 2009-11-24 2019-05-08 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
SG10201408598XA (en) * 2009-11-30 2015-02-27 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
CA2793890C (en) 2010-04-15 2017-08-15 Spirogen Developments Sarl Pyrrolobenzodiazepines and conjugates thereof
KR101839163B1 (en) 2010-06-08 2018-03-15 제넨테크, 인크. Cysteine engineered antibodies and conjugates
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
JP5987053B2 (en) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides
EP2750713B1 (en) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2013077859A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene expression signature for the prognosis of epithelial cancer
EP2809801B1 (en) 2012-01-31 2018-07-25 Speiser, Paul Non-invasive cancer diagnosis
CN104159611A (en) 2012-02-22 2014-11-19 阿莱斯亚生物疗法股份有限公司 Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
ES2703151T3 (en) 2012-10-12 2019-03-07 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates
EP2906253B9 (en) 2012-10-12 2019-04-10 ADC Therapeutics SA Pyrrolobenzodiazepine - anti-psma antibody conjugates
CN105102004B (en) 2012-10-12 2019-01-25 Adc疗法责任有限公司 Pyrrolobenzodiazepines Zhuo-anti-CD22 antibody conjugate
PT2906296T (en) 2012-10-12 2018-06-01 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ME03486B (en) 2012-10-12 2020-01-20 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
BR112015014669B1 (en) 2012-12-21 2023-09-26 Medimmune Limited PYRROLOBENZODIAZEPINE COMPOUNDS, CONJUGATES COMPRISING THE SAME AND USE THEREOF TO TREAT A PROLIFERATIVE DISEASE
CN105246894A (en) 2012-12-21 2016-01-13 斯皮罗根有限公司 Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US9297814B2 (en) * 2013-01-04 2016-03-29 Wisconsin Alumni Research Foudation Methods of detecting ovarian cancer
BR112015021965B1 (en) 2013-03-13 2022-05-03 Medimmune Limited Pyrrolobenzodiazepine conjugates and compounds, pharmaceutical composition, use thereof for the treatment of a proliferative disease and method of synthesis of said compounds
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP2968596B1 (en) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3082874A2 (en) 2013-12-16 2016-10-26 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
AU2014364927A1 (en) 2013-12-16 2016-07-07 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013258A2 (en) 2013-12-16 2018-01-16 Genentech Inc antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
MX2017003523A (en) 2014-09-17 2017-11-08 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof.
ES2941897T3 (en) 2014-11-12 2023-05-26 Seagen Inc Compounds that interact with glycans and procedures for use
BR112017011111A2 (en) 2014-11-25 2017-12-26 Adc Therapeutics Sa pyrrolobenzodiazepine-antibody conjugates
KR20170086121A (en) 2014-12-03 2017-07-25 제넨테크, 인크. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
US20200041517A1 (en) * 2015-06-12 2020-02-06 Seattle Genetics, Inc. Compositions and methods for targeting cancer stem cells
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
JP7066613B2 (en) 2015-11-12 2022-05-13 シージェン インコーポレイテッド Glycan interacting compounds and how to use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017165734A1 (en) 2016-03-25 2017-09-28 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
WO2018007573A1 (en) 2016-07-08 2018-01-11 Novozymes A/S Detergent compositions with galactanase
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (en) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 Method for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
UA125198C2 (en) 2017-02-08 2022-01-26 Ейдісі Терапьютікс Са Pyrrolobenzodiazepine-antibody conjugates
SG11201907889YA (en) 2017-03-03 2019-09-27 Seattle Genetics Inc Glycan-interacting compounds and methods of use
ES2926144T3 (en) 2017-04-18 2022-10-24 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP7408396B2 (en) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム combination therapy
WO2018229222A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
HRP20220311T1 (en) 2017-08-18 2022-05-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
BR112020004307A2 (en) 2017-09-20 2020-11-10 Ph Pharma Co., Ltd. tailanestatin analogues
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
KR102252384B1 (en) * 2018-10-08 2021-05-14 차의과학대학교 산학협력단 Analytical method for diagnosing premature ovarian failure and kit therefor
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
AU2021312225A1 (en) 2020-07-21 2023-02-16 Genentech, Inc. Antibody-conjugated chemical inducers of degradation of BRM and methods thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2023147329A1 (en) 2022-01-26 2023-08-03 Genentech, Inc. Antibody-conjugated chemical inducers of degradation and methods thereof
WO2023147328A1 (en) 2022-01-26 2023-08-03 Genentech, Inc. Antibody-conjugated chemical inducers of degradation with hydolysable maleimide linkers and methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US5356817A (en) * 1988-06-09 1994-10-18 Yale University Methods for detecting the onset, progression and regression of gynecologic cancers
DE19817557A1 (en) * 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Human nucleic acid sequences from ovarian tumor tissue
WO2001075177A2 (en) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
EP1410013A4 (en) * 2001-06-21 2006-02-01 Millennium Pharm Inc Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2004108896A2 (en) * 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
US7927795B2 (en) * 2003-06-09 2011-04-19 Board Of Trustees Of The University Of Arkansas Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
US7582441B1 (en) * 2005-10-17 2009-09-01 Celera Corporation Methods and compositions for treating and diagnosing disease

Also Published As

Publication number Publication date
WO2001075177A2 (en) 2001-10-11
US7279294B2 (en) 2007-10-09
US20030211498A1 (en) 2003-11-13
WO2001075177A3 (en) 2003-05-22
US20080253963A1 (en) 2008-10-16
US20100183507A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
AU2001253140A1 (en) Tumor markers in ovarian cancer
AU2002212527A1 (en) Thermometry-based breast cancer risk assessment
HUP0303749A3 (en) Renal cell carcinoma tumor markers
AU2003235470A1 (en) Predictive markers in cancer therapy
AU2001292802A1 (en) Genetic markers for tumors
HK1083771A1 (en) Anti-neovasculature preparations for cancer
AU2001281210A1 (en) Electromagnetic antenna
AUPR395801A0 (en) Antibodies against cancer
AU2001290860A1 (en) Spas-1 cancer antigen
AU2002360345A1 (en) Prostate cancer genes
AU2003224598A1 (en) Differentially-regulated prostate cancer genes
AU2002307154A1 (en) Prostate cancer expression profiles
AU2002362613A1 (en) Galectins-1-and-4 in tumor development
EP1208232A4 (en) Markers for prostate cancer
AU2001277857A1 (en) Tumor necrosis factor-gamma
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2001257325A1 (en) Cancer treatment
AU2001274252A1 (en) Directional antenna
AU2001232007A1 (en) Planar antenna
AU2001250828A1 (en) Immunogenic ovarian cancer genes
AU2001236189A1 (en) Bowtie antenna
AU2001236782A1 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
AU2003280693A1 (en) Prostate cancer tumor marker
AU2001290241A1 (en) Tumor cell proliferation inhibitors
AU2001238144A1 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer